Rigel Pharmaceuticals spent the second quarter turning a profitable three-drug hematology and oncology franchise into a four-product company. The vehicle is VEPPANU, the first approved protein-degrader pill for a genetically defined form of metastatic breast cancer, licensed from Arvinas and Pfizer and put on United States pharmacy shelves in mid-August. Management paid $70 million upfront to own the global commercial rights. The central debate is whether a specialty hematology sales force can launch into a crowded endocrine-resistance market without consuming the cash engine that just wrote the check.
The existing book still compounds. Net product sales rose 14% in the June quarter as TAVALISSE, the oral spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia, posted another record. REZLIDHIA, the IDH1 inhibitor for relapsed acute myeloid leukemia, kept growing at 27%. GAVRETO, the RET inhibitor taken over from Blueprint, declined after a boxed warning for serious infections. Contract revenue from partners added a high-margin overlay, including a Kissei milestone tied to a Japan filing for olutasidenib. Full-year product guidance was left unchanged and still excludes any VEPPANU contribution, which is an honest tell that the launch is not yet in the model.
Cash stood at $95 million at mid-year after the license payment, a MidCap refinance, and the last Blueprint installment. Operating cash flow stayed positive in the first half, which is the fact that makes the deal rational rather than reckless. The next two quarters resolve a single question. Does early VEPPANU demand look like a franchise product, or like a scientifically elegant niche that a hematology company overpaid to own?